Rates of VTE in Newly Diagnosed MM Treatment No Prophylaxis Any Prophylaxis ASA Warfarin 1125 mgd Prophylactic LMWH Therapeutic Anticoagulation T alone 95 CI 13 0427 ID: 585927
Download Presentation The PPT/PDF document "Thalidomide-based Regimens:" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Thalidomide-based Regimens: Rates of VTE* in Newly Diagnosed MM
TreatmentNo ProphylaxisAny ProphylaxisASAWarfarin1-1.25 mg/dProphylactic LMWHTherapeutic AnticoagulationT alone (95% CI) 1.3 (0.4–2.7) (n=380)NANANA0.5 (0.4–0.6) (n=64)NATD (95% CI)4.1 (2.8–5.9) (n=628)2.6 (2.1–3.2) (n=993)2.3 (0.9–7.9) (n=80)2.8 (2–3.9) (n=387)2.1 (1.1–3.6) (n=446)1.6(0.2–4.1)(n=80)*per 100 patient-cyclesASA=aspirin; LMWH=low molecular weight heparin; MM=multiple myeloma; T=thalidomide; TD=thalidomide + dexamethasone; VTE=venous thromboembolism
1090Slide2
Thalidomide-based Regimens: Rates of VTE* in Previously Treated MM
TreatmentNo prophylaxisASAWarfarin 1-1.25 mg/dProphylactic LMWHTherapeutic Doses of AnticoagulationT alone (95% CI)0.4 (0.2–0.8) (n=706)NANA0 (0–1.72) (n=17)NAT+ prednisone (95% CI)0.6 (0.2–1.1) (n=258)NANANANATC (95% CI)0.4 (0.01–1.2) (n=38)0.4 (0.01–0.9) (n=37)NANATD (95% CI)0.8 (0.1–2.1)
(n=321)
NA
NANANATDC agents (95% CI)0.9 (0.3–1.8) (n=321)NA2.4 (1.3–4) (n=102)NA0 (0–2.2) (n=18)TDC including doxorubicin (95% CI)6.7 (0.5–18.9) (n=331)NA3.5 (1.2–6.5) (n=50)NALenalidomide-based regimens*per 100 patient-monthsASA=aspirin; LMWH=low molecular weight heparin; MM=multiple myeloma; T=thalidomide; TC=thalidomide + cytotoxic chemotherapy; TD=thalidomide + dexamethasone; TDC=thalidomide + dexamethasone + cytotoxic chemotherapy; VTE=venous thromboembolism
1090Slide3
Lenalidomide-based Regimens
Rates of VTE (per 100 patient-cycles) in patients with newly diagnosed MMTreatmentNo ProphylaxisAny ProphylaxisASALD (95% CI)0.8 (0.07–2) (n=278)0.7 (0.5–1.1) (n=349)0.9 (0.5–1.5) (n=172)Rate of VTE (per 100 patient-months) in patients with previously treated MMTreatmentNo ProphylaxisASALD (95% CI)0.7(0.4–0.9)(n=361)NALDC including doxorubicin (95% CI)NA0.6 (0.01–2.1) (n=131)None of the studies reported major bleeding events. ASA=aspirin; LD=lenalidomide + dexamethasone; VTE=venous thromboembolism1090